Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q3 2014 · 10-Q
Revenue$261.00K$261.00K+1.2% vs Q3 2013 Net Income-$2.05M-$2.05MN/M vs Q3 2013 EPS Diluted-$0.07-$0.07N/M vs Q3 2013 Operating Income-$2,184,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,366,000N/M Margins · derivedOperating margin-836.8%−225.5 pt vs Q3 2013
Net margin-785.1%−190.5 pt vs Q3 2013
ended Apr 30, 2014 · filed Jun 10, 2014 · 41 d after period end